1. |
Sun Y, Christensen J, Hviid A, et al. Risk of febrile seizures and epilepsy after vaccination with diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and haemophilus influenzae type b. JAMA, 2012, 307(8): 823-831.
|
2. |
Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis, 2021, 21(2): 181-192.
|
3. |
Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, 2020, 396(10249): 479-488.
|
4. |
Keech C, Albert G, Cho I, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med, 2020, 383(24): 2320-2332.
|
5. |
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med, 2020, 383(27): 2603-2615.
|
6. |
Ella R, Vadrevu KM, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis, 2021, 21(5): 637-646.
|
7. |
Ella R, Reddy S, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Disease, 2021, S1473-3099(21): 00070-0.
|
8. |
Voysey Merryn et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 2020, 397(10269): 99-111.
|
9. |
Chu Laurence et al. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine, 2021, 39(20): 2791-2799.
|
10. |
Doroftei Bogdan et al. Mini-review discussing the reliability and efficiency of COVID-19 vaccines. Diagnostics, 2021, 11(4): 579.
|
11. |
Logunov Denis Y et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet, 2021, 397(10275): 671-681.
|
12. |
Xia Shengli et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA, 2020, 324(10): 951-960.
|
13. |
Sadoff Jerald et al. Interim results of a phase 1–2a trial of Ad26. COV2. S Covid-19 vaccine. New England Journal of Medicine, 2021, 384(19): 1824-1835.
|
14. |
Xiang Wang. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine, 2021, 384(16): 1576-1578.
|
15. |
中国抗癫痫协会. 临床诊疗指南癫痫病分册(2015修订版)[M]. 北京: 人民卫生出版社, 2015: 15-16.
|
16. |
Deng L, Wood N, Danchin M. Seizures following vaccination in children: Risks, outcomes and management of subsequent revaccination. Aust J Gen Pract, 2020, 49(10): 644-649.
|
17. |
叶盛. 特殊健康状态儿童预防接种专家共识之八——癫痫与预防接种. 中国实用儿科杂志, 2019, 34(02): 82-84.
|
18. |
Reyes IS, Hsieh DT, Laux LC, et al. Alleged cases of vaccine encephalopathy rediagnosed years later as Dravet syndrome. Pediatrics, 2011, 128(3): e699-702.
|